Öz
Spondiloartropatinin bir türü olan ankilozan spondilit (AS), esas olarak aksiyel iskelet, sakroiliak eklem, tendonlar ve bağlar gibi yumuşak dokuları etkileyebilen enflamasyonla karakterize otoimmün bir hastalıktır. AS tedavisinin amaçları omurga esnekliğini geri kazandırmak, postürü iyileştirmek, semptomları hafifletmek, fonksiyonel kısıtlamaları önlemek ve komplikasyonları azaltmaktır. Farmakolojik tedavi basamaklarında, non-steroid anti-enflamatuvar ilaçlarla tedaviye rağmen yüksek hastalık aktivitesi olan hastaların anti-tümör nekroz faktörü (TNF)-alfa ve interlökin-17 inhibitörlerini içeren biyolojik ajanlarla tedavi edilmesi önerilmektedir. Biyolojik ajanlarla tedavi edilen olgularda ciddi enfeksiyon riski göz önünde bulundurulmalıdır. Kronik hepatit B enfeksiyonu olan hastalarda uygun antiviral profilaksi olmadan verilen anti-TNF-alfa ajanlarının viral reaktivasyonu indüklediği gösterilmiştir. Bu nedenle, antiviral tedavi ile birlikte kullanılmaları önerilmektedir. Ancak literatürde antiviral profilaksiye rağmen hepatit reaktivasyonunun görüldüğü nadir vakalar bildirilmiştir. Biz de anti TNF-alfa ajanının profilaktik bir antiviral ilaç ile birlikte kullanılmasına rağmen hepatit-B reaktivasyonu gelişen bir olguyu sunmayı amaçladık.
Anahtar Kelimeler: Anahtar kelimeler: Hepatit-B enfeksiyonu, spondiloartropati, ankilozan spondilit, hepatit reaktivasyonu, anti tümör nekroz faktör alfa
Kaynakça
Zhu W, He X, Cheng K, Zhang L, Chen D, Wang X, et al. Ankylosing spondylitis: etiology, pathogenesis, and treatments. Bone Res. 2019;7:22
Akkoc N. Are spondyloarthropathies as common as rheumatoid arthritis worldwide? A review. Curr Rheumatol Rep. 2008;10:371-8.
Ward MM, Deodhar A, Akl EA, Lui A, Ermann J, Gensler LS, et al. American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol. 201668:282-98.
Global hepatitis report, 2017. Accessed: April 10, 2023: Available from: https://www.who.int/publications/i/item/9789241565455.
Yılmaz N, Karadağ Ö, Kimyon G, Yazıcı A, Yılmaz S, Kalyoncu U, et al. Prevalence of hepatitis B and C infections in rheumatoid arthritis and ankylosing spondylitis: A multicenter countrywide study. Eur J Rheumatol. 2014;1:51-4.
Ekpanyapong S, Reddy KR. Hepatitis B Virus Reactivation: What Is the Issue, and How Should It Be Managed? Clin Liver Dis. 2020;24:317-33.
Vassilopoulos D, Apostolopoulou A, Hadziyannis E, Papatheodoridis GV, Manolakopoulos S, Koskinas J, et al. Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Ann Rheum Dis. 2010;69:1352-5.
Pyrpasopoulou A, Douma S, Vassiliadis T, Chatzimichailidou S, Triantafyllou A, Aslanidis S. Reactivation of chronic hepatitis B virus infection following rituximab administration for rheumatoid arthritis. Rheumatol Int. 2011;31:403-4.
Nunes GPS, Cunha PDS, Bosco DPD, Ribeiro SLE. Challenging Management of Hepatitis B infection in Ankylosing Spondylitis Patients in an Endemic Area during Immunosuppressive Therapy. Rev Soc Bras Med Trop. 2019;52:20180386.
Mori S, Fujiyama S. Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations. World J Gastroenterol. 2015;21:10274-89.
Lau GK, Leung YH, Fong DY, Au WY, Kwong YL, Lie A, et al. High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. Blood. 2002;99:2324-30.
Conjeevaram HS, Lok AS. Management of chronic hepatitis B. J Hepatol. 2003;38:90-103.
Ye H, Zhang XW, Mu R, Fang LK, Gu JR, Lin J, et al. Anti-TNF therapy in patients with HBV infection--analysis of 87 patients with inflammatory arthritis. Clin Rheumatol. 2014;33:119-23.
Su J, Long L, Zou K. Antiviral prophylaxis for preventing reactivation of hepatitis B virus in rheumatic patients: a systematic review and meta-analysis. Clin Rheumatol. 2018;37:3201-14.
Pérez-Alvarez R, Díaz-Lagares C, García-Hernández F, Lopez-Roses L, Brito-Zerón P, Pérez-de-Lis M, et al. BIOGEAS Study Group. Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine (Baltimore). 2011;90:359-71.
Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148:221-44.
Chotiyaputta W, Lok AS. Hepatitis B virus variants. Nat Rev Gastroenterol Hepatol. 2009;6:453-62.
Lee YH, Bae SC, Song GG. Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy. Clin Exp Rheumatol. 2013;31:118-21.
Pei SN, Chen CH. Risk and prophylaxis strategy of hepatitis B virus reactivation in patients with lymphoma undergoing chemotherapy with or without rituximab. Leuk Lymphoma. 2015;56:1611-8.
